Both in Pharmaceuticals
Akebia Therapeutics vs Keros Therapeutics
Over the past year AKBA returned −65.8% and KROS returned −27.9%; their daily moves had a correlation of 0.20.
AKBA −65.8% KROS −27.9%Growth of $1, one year, split-adjusted
| Metric | AKBA | KROS |
|---|---|---|
| Price | $0.7252 | $10.97 |
| Market cap | $201.0M | $217.5M |
| Today | −0.08% | +1.29% |
| 1 month | −17.5% | −0.4% |
| 6 months | −51.0% | −6.9% |
| Year to date | −55.0% | −46.1% |
| 1 year | −65.8% | −27.9% |
| Revenue growth (YoY) | −21.4% | −100.0% |
| Gross margin | 78.8% | — |
| Net margin | −18.1% | — |
| P/E (TTM) | — | — |
| Price / sales | 0.9× | 14.5× |
| Net cash | $106.0M | $257.6M |
| Dividend yield | — | — |
| Volatility (60d) | 71.8% | 43.3% |
| Short % of float | 8.7% | 6.2% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).